DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DMAC DiaMedica Therapeutics Inc.

Market Closed 04-24 16:00:00 EDT

6.33

+0.11

+1.77%

盘后6.33

+0.000.00%

17:08 EDT

High6.35	Low6.00	Vol130.99K
Open6.20	D1 Closing6.22	Amplitude5.63%
Mkt Cap341.08M	Tradable Cap208.54M	Total Shares53.88M
T/O819.33K	T/O Rate0.40%	Tradable Shares32.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DMAC","market":"US","secType":"STK","nameCN":"DiaMedica Therapeutics Inc.","latestPrice":6.33,"timestamp":1777060800000,"preClose":6.22,"halted":0,"volume":130987,"hourTrading":{"tag":"盘后","latestPrice":6.33,"preClose":6.33,"latestTime":"17:08 EDT","volume":1939,"amount":12273.87,"timestamp":1777064907179,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017684887459807126,"floatShares":32944600,"shares":53882506,"eps":-0.7,"marketStatus":"Market Closed","change":0.11,"latestTime":"04-24 16:00:00 EDT","open":6.2,"high":6.35,"low":6,"amount":819333.4435315001,"amplitude":0.05627,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.7,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1777276800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":6.22,"postHourTrading":{"tag":"盘后","latestPrice":6.33,"preClose":6.33,"latestTime":"17:08 EDT","volume":1939,"amount":12273.87,"timestamp":1777064907179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8288145434492399,"impliedVol":0.6258,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/DMAC/tweets","defaultTab":"tweets","newsList":[{"id":"2628275846","title":"Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275846","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628275846?lang=en_us&edition=fundamental","pubTime":"2026-04-18 21:08","pubTimestamp":1776517738,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/companies-like-diamedica-therapeutics-nasdaqdmac-are-in-a-po","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmac/diamedica-therapeutics/news/companies-like-diamedica-therapeutics-nasdaqdmac-are-in-a-po","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["JEPQ","BK4139","NQmain","QQQY","QQQM","DMAC","PSQ","NVIW.SI",".IXIC","FTEC","IYW","QID","NDX","QLD","QQQA","ONEQ","TQQQ","QQQE","GPIQ","QQQ","TQQY","SQQQ","MNQmain","QYLG","QQQJ","QDTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624418625","title":"DiaMedica Therapeutics publishes 2025 annual report, sees cash runway through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2624418625","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624418625?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:24","pubTimestamp":1775075080,"startTime":"0","endTime":"0","summary":"DiaMedica annual report for fiscal year 2025 highlighted continued development of lead candidate DM199 across preeclampsia and acute ischemic stroke programs.Health Canada issued a “No Objection” letter enabling a DiaMedica-sponsored Phase 2 dose-ranging study in early-onset preeclampsia.ReMEDy2 Phase 2/3 pivotal trial in acute ischemic stroke reported improving site activation and enrollment following protocol refinements.Board expansion added Dan O’Connor, citing experience from Ambryx Biopharma acquisition by Johnson & Johnson in 2024.Operating runway guidance reaffirmed through end of 2027, supporting current development plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2LKCS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0234572021.USD","BK4533","LU2505996681.GBP","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4592","LU2471134523.USD","IE0034235303.USD","IE0002270589.USD","LU0994945656.USD","LU2112291526.USD","LU0795875086.SGD","BK4534","IE00BDGV0183.EUR","LU1261432733.SGD","IE00B3T34201.USD","BK4559","IE00BLSP4239.USD","LU1244550494.USD","LU0426412945.USD","IE00B1BXHZ80.USD","LU0882574055.USD","LU1732800096.USD","LU2471134879.HKD","IE00BKVL7J92.USD","LU1894683348.USD","JNJ","LU2347655156.SGD","IE00BSNM7G36.USD","IE0001KFT4U8.USD","IE0002141913.USD","DMAC","IE00B3PB1722.GBP","LU1585245621.USD","LU2602419157.SGD","LU1244550577.SGD","LU0432979614.USD","LU1221951046.USD","LU2750360997.AUD","LU1061106388.HKD","LU0234570918.USD","LU1244550221.USD","BK4568","LU0058720904.USD","LU0466842654.USD","LU0345769631.USD","LU2089984988.USD","LU1032955483.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624054918","title":"DiaMedica Therapeutics announces annual shareholder meeting notice and proxy statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624054918","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624054918?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074133,"startTime":"0","endTime":"0","summary":"DiaMedica set annual general meeting for May 20, 2026 in Minneapolis, Minnesota.Ballot includes ratification of Baker Tilly US as independent auditor for fiscal 2026.Meeting will also consider amended and restated 2019 omnibus incentive plan, including a 3,500,000-share increase in shares available for issuance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL8pZvjS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624751623","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624751623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624751623?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:50","pubTimestamp":1775047837,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-diamedica-therapeutics-dmac-elevance-health-elv-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-diamedica-therapeutics-dmac-elevance-health-elv-and-oric-pharmaceuticals-oric-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1057294990.SGD","LU2362541513.USD","LABU","DMAC","SGXZ23171101.USD","LU0266013472.USD","LU0114720955.EUR","BK4588","LU0130102774.USD","LU0957791311.USD","LU0211331839.USD","LU0208291251.USD","LU0648001328.SGD","LU0289739699.SGD","LU2357305700.SGD","LU0006306889.USD","LU0251142724.SGD","BK4581","LU1489326972.SGD","SG9999003800.SGD","LU0128526141.USD","LU0320765489.SGD","BK4585","LU0106261372.USD","LU2362540622.SGD","LU0640476718.USD","LU0314106906.USD","LU0068578508.USD","XLV","LU0742534661.SGD","LU0345770308.USD","LU1720051108.HKD","LU2362541273.HKD","LU0345770993.USD","LU0029874061.USD","ORIC","HCSG","LU1201861249.SGD","LU1815333072.USD","LU0557290698.USD","LU2505996509.AUD","LU0477156953.USD","LU0058720904.USD","LU2108987350.USD","LU0878866978.SGD","LU2430703095.HKD","ELV","LU1983299246.USD","LU1720051017.SGD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373672","title":"DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373672","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623373672?lang=en_us&edition=fundamental","pubTime":"2026-03-31 08:49","pubTimestamp":1774918153,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryDiaMedica Therapeutics Inc DMAC.OQ reported a quarterly adjusted loss of 17 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623321349","title":"DiaMedica FY25 net loss widens to $33 million; R&D expenses rise to $25 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623321349","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623321349?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:45","pubTimestamp":1774903531,"startTime":"0","endTime":"0","summary":"DiaMedica posted a net loss of $33 million, with loss per share of $0.70 for fiscal 2025.Operating loss widened to $34 million, while R&D expense climbed to $25 million.Cash and short-term investments rose to $60 million, with operating cash outflow of $29 million.Health Canada issued a No Objection Letter supporting initiation of a Phase 2 DM199 study in early-onset preeclampsia, while ReMEDy2 acute ischemic stroke trial enrollment approached 70% of interim target.Cash runway expected to fund operations through 2H 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6kvZhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623213083","title":"Press Release: DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2623213083","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623213083?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:45","pubTimestamp":1774903500,"startTime":"0","endTime":"0","summary":"of Phase 2 DM199 Study in Early-onset Preeclampsia.--  DM199 Preeclampsia Phase 2 Investigator-Sponsored Trial  Part 1a. Expansion Cohort Enrolling, Completion Expected in 1H 2026.--  ReMEDy2 Phase 2/3 AIS Trial of DM199 Approaching 70% of Required. --  $60 million in Cash, Cash Equivalents and Investments, Anticipated. --  Conference Call and Webcast on March 31 at 8:00 AM ET / 7:00 AM CT.--  Part 1b  and Part 2 (early onset. PE with expectant management): Based on clinical learnings from Part 1a,treatment regimen, with initiation expected following completion of the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4233","BK4539","BK4528","BK4007","BK4205","AIS","DMAC","LENZ","UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BITF","PVH","PRGS","ANGO","RNXT","BEEM","AIRO","NKLR","CRDL","CAG","BNZI","BCAX","NNOX","MKC","BTBT","AURA","BIRD","PENG","AIRJ","FDS","CALM","KEEL","SGML","BYND","MSM","NCNO","PLAY","JILL","RH","IMNN","PHR","PROP","PVLA","INV","MKC.V","MAZE","LNN","NEOG","SGMO","INMB","AYI","NKE","PRPL","DMAC","NMRA","FC","AEHR","APOG","LW","NGEN","BHST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622380811","title":"DiaMedica Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622380811","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622380811?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:31","pubTimestamp":1774643466,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to  show no change in quarterly revenue when it reports  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F21G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMAC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APOG","INV","BEEM","HUMA","AEHR","BITF","AYI","KEEL","AIRO","CALM","BCAX","PHR","FDS","NEOG","PLAY","ANGO","BIRD","MKC","AURA","PENG","PRGS","BNZI","JILL","NCNO","NGEN","ATOS","CRDL","MKC.V","CCL","LNN","FC","KOPN","MSLE","NKE","BYND","BTBT","NKLR","RNXT","AIRJ","CAG","LW","INMB","KYTX","DEFT","IMNN","MSM","DMAC","BHST","AUTL","NMRA","LGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BYND","BIRD","CELC","BNZI","EDAP","KALV","CNTA","FEMY","FUL","CGTX","GOVX","JILL","DMAC","BITF","BTGO","FDS","CGNT","DEFT","CCL","NKE","AUTL","AGX","DERM","ABOS","CDLR","HUMA","HYPD","IKT","KOD","IMDX","BAK","IMNN","JEF","CNTX","AIRJ","AIRO","BHST","RNXT","EQ","CTAS","DOO","CNTB","AURA","EPAC","JBS","MKC","BCAX","CMC","CHWY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2621888705","title":"DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2621888705","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621888705?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:25","pubTimestamp":1774268712,"startTime":"0","endTime":"0","summary":"DiaMedica will release its full-year 2025 financial results after the markets close on March 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDLcfYrPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621705703","title":"DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621705703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621705703?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:25","pubTimestamp":1774268700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA375JKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619199631","title":"DiaMedica Therapeutics Inc  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619199631","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619199631?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:05","pubTimestamp":1773399906,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc  expected to post a loss of18cents a share - Earnings Preview DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N4010W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618762234","title":"Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618762234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618762234?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:20","pubTimestamp":1773066033,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Savara (SVRA – Research Report), Codexis (CDXS – Res...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-savara-svra-codexis-cdxs-and-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-savara-svra-codexis-cdxs-and-diamedica-therapeutics-dmac-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4588","SVRA","BK4139","BK4121","HCSG","XBI","CDXS","LU0128526141.USD","XLV","BK4581","DMAC","BK4137","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617547686","title":"DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2617547686","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617547686?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:59","pubTimestamp":1772715578,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics (DMAC) announced that it has received a no objection letter from Health Canada for its clinical trial application to evaluat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/diamedica-therapeutics-receives-health-canada-clearance-to-initiate-dm199-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/diamedica-therapeutics-receives-health-canada-clearance-to-initiate-dm199-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","DMAC","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617542869","title":"Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2617542869","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617542869?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:35","pubTimestamp":1772714112,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. said it received a No Objection Letter from Health Canada clearing its Clinical Trial Application to evaluate DM199 in a Phase 2 trial for early-onset preeclampsia. The company said the clearance allows it to initiate the open-label, dose-ranging study in Canada, with plans to expand into the United States and United Kingdom after obtaining additional regulatory clearances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on March 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL6skcpP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617889542","title":"DiaMedica Therapeutics Inc - to Initiate Phase 2 Dm199 Trial in 2026; US and UK Expansion Planned","url":"https://stock-news.laohu8.com/highlight/detail?id=2617889542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617889542?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:35","pubTimestamp":1772714100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA6J4XTB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617544056","title":"DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of Dm199 in Preeclampsia","url":"https://stock-news.laohu8.com/highlight/detail?id=2617544056","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617544056?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:35","pubTimestamp":1772714100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA6J4XTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMAC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613710893","title":"DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613710893","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613710893?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:23","pubTimestamp":1771942991,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc. said management will participate in three investor conferences in March 2026: a TD Cowen 46th Annual Healthcare Conference fireside chat in Boston on March 2, 2026; a Barclays 28th Annual Global Healthcare Conference fireside chat in Miami on March 10, 2026; and a Leerink Partners Global Healthcare Conference presentation in Miami on March 11, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on February 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL7rGRVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAC","MNSH","BK4139","BK4207"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.diamedica.com","stockEarnings":[{"period":"1week","weight":-0.0759},{"period":"1month","weight":-0.0773},{"period":"3month","weight":-0.2562},{"period":"6month","weight":-0.0799},{"period":"1year","weight":0.518},{"period":"ytd","weight":-0.2048}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.087},{"period":"3month","weight":0.0359},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.3059},{"period":"ytd","weight":0.047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.044661},{"month":2,"riseRate":0.75,"avgChangeRate":0.065241},{"month":3,"riseRate":0.125,"avgChangeRate":-0.104653},{"month":4,"riseRate":0.5,"avgChangeRate":0.012978},{"month":5,"riseRate":0.571429,"avgChangeRate":0.093378},{"month":6,"riseRate":0.571429,"avgChangeRate":0.181571},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.11728},{"month":8,"riseRate":0.571429,"avgChangeRate":0.048626},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.090818},{"month":10,"riseRate":0.571429,"avgChangeRate":0.039154},{"month":11,"riseRate":0.857143,"avgChangeRate":0.137742},{"month":12,"riseRate":0.571429,"avgChangeRate":0.246007}],"exchange":"NASDAQ","name":"DiaMedica Therapeutics Inc.","nameEN":"DiaMedica Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DiaMedica Therapeutics Inc.,DMAC,DiaMedica Therapeutics Inc.股票,DiaMedica Therapeutics Inc.股票老虎,DiaMedica Therapeutics Inc.股票老虎国际,DiaMedica Therapeutics Inc.行情,DiaMedica Therapeutics Inc.股票行情,DiaMedica Therapeutics Inc.股价,DiaMedica Therapeutics Inc.股市,DiaMedica Therapeutics Inc.股票价格,DiaMedica Therapeutics Inc.股票交易,DiaMedica Therapeutics Inc.股票购买,DiaMedica Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DiaMedica Therapeutics Inc.(DMAC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DiaMedica Therapeutics Inc.(DMAC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}